EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity

Julian Schmidt, Caroline Bockhard, Lea Simon, Gregor M Linden, Johannes M Scheiger, Holger Frey

Advanced Drug Delivery Reviews · 2026-11 · 238 · 115943

DOI: 10.1016/j.addr.2026.115943 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-11. Verfasst von Julian Schmidt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. Electronic address: julian.schmidt@uni-mainz.d…. Hauptthemen laut MEDLINE: Polyethylene Glycols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Research Council, Horizon Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PEGylation is a crucial strategy in modern nanomedicine, offering effective and safer therapeutics. However, the growing prevalence of anti-PEG antibodies (APAs) in patients has raised critical concerns, with multiple studies demonstrating reduced clinical efficacy and safety risks associated with APA formation. This has generated broad consensus on the need for next-generation nanomedicine solutions, leading to the development of several promising alternatives to PEG. However, antibodies against some alternatives have already been reported. Furthermore, full understanding of PEG immunogenicity and clinical impact is highly relevant before switching to another polymeric structure. Therefore, a detailed consideration of immunogenicity and molecular recognition patterns is recommended to guide the next generation of nanomedicine. To address these challenges, the randomized PEG (rPEG) technology has recently been introduced, capitalizing on APA structure knowledge. The random incorporation of "synthetic point mutations", i.e., glycidyl methyl ether, disrupts the regularity of PEG, while preserving the polyether key properties. Reduced antigenicity of rPEG was confirmed via ELISA, MST, and FCS analysis. Further in vitro studies demonstrated that rPEG is noncytotoxic, does not interact with blood, and is unlikely to activate complement. In nanoparticle applications, rPEG-based polymeric micelles and lipid nanoparticles exhibited reduced antigenicity and comparable mRNA transfection efficiency to their PEGylated counterparts, respectively. Recent in vivo studies demonstrated that rPEG-liposomes, across a series of PEG alternatives, were the only formulations that did not exhibit accelerated blood clearance, even following cross-immunization with PEGylated liposomes. Although stealth performance requires further optimization, rPEG represents a highly promising PEG alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polyethylene GlycolsHumansAnimalsNanoparticlesNanomedicineAntibodies

Stichwörter der Autor:innen

Accelerated blood clearanceAnti-PEG antibodyNanomedicineNanoparticlePEG immunogenicityPEGylationrandomized PEG (rPEG)

Substanzen

Polyethylene GlycolsAntibodies

Autor:innen und Institutionen

  • Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. Electronic address: julian.schmidt@uni-mainz.de.
  • Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. Electronic address: c.bockhard@uni-mainz.de.
  • Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. Electronic address: leasimon@uni-mainz.de.
  • Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. Electronic address: linden@uni-mainz.de.
  • Evonik Operations GmbH, Kirschenallee 45, 64293 Darmstadt, Germany. Electronic address: johannes.scheiger@evonik.com.
  • Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128 Mainz, Germany. Electronic address: hfrey@uni-mainz.de.

Förderung

  • European Research Council
  • Horizon Europe

Zitieren

APA

Schmidt, J., Bockhard, C., Simon, L., Linden, G. M., Scheiger, J. M., & Frey, H. (2026). From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity. Advanced Drug Delivery Reviews, 238, 115943. https://doi.org/10.1016/j.addr.2026.115943

Vancouver

Schmidt J, Bockhard C, Simon L, Linden GM, Scheiger JM, Frey H. From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity. Advanced Drug Delivery Reviews. 2026;238:115943. doi:10.1016/j.addr.2026.115943

BibTeX
@article{Schmidt2026,
  author = {Schmidt, Julian and Bockhard, Caroline and Simon, Lea and Linden, Gregor M and Scheiger, Johannes M and Frey, Holger},
  title = {From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {238},
  pages = {115943},
  doi = {10.1016/j.addr.2026.115943}
}
Kostenlos starten →